|Other Names||Chordin-like protein 1, Neuralin-1, Neurogenesin-1, Ventroptin, CHRDL1, NRLN1|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Antagonizes the function of BMP4 by binding to it and preventing its interaction with receptors. Alters the fate commitment of neural stem cells from gliogenesis to neurogenesis. Contributes to neuronal differentiation of neural stem cells in the brain by preventing the adoption of a glial fate. May play a crucial role in dorsoventral axis formation. May play a role in embryonic bone formation (By similarity). May also play an important role in regulating retinal angiogenesis through modulation of BMP4 actions in endothelial cells. Plays a role during anterior segment eye development.|
|Tissue Location||Expressed in the developing cornea and in the eye anterior segment in addition to the retina. Differentially expressed in the fetal brain. There is high expression in cerebellum and neocortex. Expressed in retinal pericytes|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CHRDL1 is an antagonist of bone morphogeneticprotein 4. The encoded protein may play a role in topographicretinotectal projection and in the regulation of retinalangiogenesis in response to hypoxia. Alternatively splicedtranscript variants encoding different isoforms have beendescribed.
Fernandes, H., et al. Cells Tissues Organs (Print) 191(6):443-452(2010)Larman, B.W., et al. J. Am. Soc. Nephrol. 20(5):1020-1031(2009)Kane, R., et al. Mol. Vis. 14, 1138-1148 (2008) :Kosinski, C., et al. Proc. Natl. Acad. Sci. U.S.A. 104(39):15418-15423(2007)Gazzerro, E., et al. Rev Endocr Metab Disord 7 (1-2), 51-65 (2006) :
If you have any additional inquiries please email technical services at firstname.lastname@example.org.